Bevirimat dimeglumine | CAS# 823821-85-8 | treatment of HIV Infection

MedKoo Cat#: 413941 | Name: Bevirimat dimeglumine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bevirimat dimeglumine is used in the treatment of HIV Infection

Chemical Structure

Bevirimat dimeglumine

CAS#823821-85-8 (dimeglumine)

Theoretical Analysis

MedKoo Cat#: 413941

Name: Bevirimat dimeglumine

CAS#: 823821-85-8 (dimeglumine)

Chemical Formula: C50H90N2O16

Exact Mass: 974.6290

Molecular Weight: 975.27

Elemental Analysis: C, 61.58; H, 9.30; N, 2.87; O, 26.25

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Bevirimat dimeglumine; PA457; PA 457; PA-457; PA457N; PA 457N; PA-457N

IUPAC/Chemical Name

(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentaol hemi((1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-((3-carboxylato-3-methylbutanoyl)oxy)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysene-3a-carboxylate)

InChi Key

TXIOIJSYWOLKNU-FLQODOFBSA-N

InChi Code

InChI=1S/C36H56O6.2C7H17NO5/c1-21(2)22-12-17-36(30(40)41)19-18-34(8)23(28(22)36)10-11-25-33(7)15-14-26(42-27(37)20-31(3,4)29(38)39)32(5,6)24(33)13-16-35(25,34)9;2*1-8-2-4(10)6(12)7(13)5(11)3-9/h22-26,28H,1,10-20H2,2-9H3,(H,38,39)(H,40,41);2*4-13H,2-3H2,1H3/t22-,23+,24-,25+,26-,28+,33-,34+,35+,36-;2*4-,5+,6+,7+/m000/s1

SMILES Code

CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.CC([C@@H]1CC[C@]2(C(O)=O)CC[C@@]3([C@@H]([C@@H]12)CC[C@@H]4[C@]5(CC[C@@H](C(C)([C@@H]5CC[C@@]34C)C)OC(CC(C)(C(O)=O)C)=O)C)C)=C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 975.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kleinpeter AB, Freed EO. HIV-1 Maturation: Lessons Learned from Inhibitors. Viruses. 2020 Aug 26;12(9):940. doi: 10.3390/v12090940. PMID: 32858867; PMCID: PMC7552077. 2: Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, Castillo A, Zoumplis D, Martin DE, Orenstein JM, Allaway GP, Freed EO, Wild CT. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13555-60. doi: 10.1073/pnas.2234683100. Epub 2003 Oct 22. PMID: 14573704; PMCID: PMC263852. 3: Li F, Zoumplis D, Matallana C, Kilgore NR, Reddick M, Yunus AS, Adamson CS, Salzwedel K, Martin DE, Allaway GP, Freed EO, Wild CT. Determinants of activity of the HIV-1 maturation inhibitor PA-457. Virology. 2006 Dec 5-20;356(1-2):217-24. doi: 10.1016/j.virol.2006.07.023. Epub 2006 Aug 22. PMID: 16930665. 4: Adamson CS, Ablan SD, Boeras I, Goila-Gaur R, Soheilian F, Nagashima K, Li F, Salzwedel K, Sakalian M, Wild CT, Freed EO. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). J Virol. 2006 Nov;80(22):10957-71. doi: 10.1128/JVI.01369-06. Epub 2006 Sep 6. PMID: 16956950; PMCID: PMC1642185. 5: Wen Z, Stern ST, Martin DE, Lee KH, Smith PC. Structural characterization of anti-HIV drug candidate PA-457 [3-O-(3',3'-dimethylsuccinyl)-betulinic acid] and its acyl glucuronides in rat bile and evaluation of in vitro stability in human and animal liver microsomes and plasma. Drug Metab Dispos. 2006 Sep;34(9):1436-42. doi: 10.1124/dmd.106.009233. Epub 2006 Jun 2. PMID: 16751262. 6: De Clercq E. Emerging anti-HIV drugs. Expert Opin Emerg Drugs. 2005 May;10(2):241-73. doi: 10.1517/14728214.10.2.241. PMID: 15934866. 7: Molecule of the month. PA-457. Drug News Perspect. 2004 May;17(4):283. PMID: 15334176. 8: James JS. PA-457, new kind of antiretroviral: ten-day clinical trial results. AIDS Treat News. 2005 Aug 26;(414):7-8. PMID: 16206398. 9: Schlicksup CJ, Zlotnick A. Viral structural proteins as targets for antivirals. Curr Opin Virol. 2020 Dec;45:43-50. doi: 10.1016/j.coviro.2020.07.001. Epub 2020 Aug 7. PMID: 32777753. 10: Regueiro-Ren A, Dicker IB, Hanumegowda U, Meanwell NA. Second Generation Inhibitors of HIV-1 Maturation. ACS Med Chem Lett. 2019 Feb 8;10(3):287-294. doi: 10.1021/acsmedchemlett.8b00656. PMID: 30891128; PMCID: PMC6421530.